600671 天目药业
已收盘 12-31 15:00:00
资讯
新帖
简况
每周股票复盘：天目药业（600671）股东会通过续聘会计师事务所议案
证券之星 · 2025-12-28
每周股票复盘：天目药业（600671）股东会通过续聘会计师事务所议案
天目药业（600671）披露全资子公司收到药品再注册批准通知书，12月18日股价上涨3.16%
证券之星 · 2025-12-18
天目药业（600671）披露全资子公司收到药品再注册批准通知书，12月18日股价上涨3.16%
天目药业（600671）披露拟续聘2025年度审计机构，12月15日股价上涨1.68%
证券之星 · 2025-12-15
天目药业（600671）披露拟续聘2025年度审计机构，12月15日股价上涨1.68%
天目药业（600671）披露召开2025年第四次临时股东会通知，12月05日股价上涨1.89%
证券之星 · 2025-12-05
天目药业（600671）披露召开2025年第四次临时股东会通知，12月05日股价上涨1.89%
每周股票复盘：天目药业（600671）公司及子公担保余额达17,525.04万元
证券之星 · 2025-11-16
每周股票复盘：天目药业（600671）公司及子公担保余额达17,525.04万元
天目药业（600671）披露为子公司提供担保及子公司为公司提供担保的进展公告，11月11日股价上涨0.96%
证券之星 · 2025-11-11
天目药业（600671）披露为子公司提供担保及子公司为公司提供担保的进展公告，11月11日股价上涨0.96%
天目药业（600671）披露子公司取得换发后的《药品生产许可证》，11月05日股价下跌1.84%
证券之星 · 2025-11-05
天目药业（600671）披露子公司取得换发后的《药品生产许可证》，11月05日股价下跌1.84%
天目药业（600671）披露子公司取得换发后的《药品生产许可证》，11月03日股价上涨1.48%
证券之星 · 2025-11-03
天目药业（600671）披露子公司取得换发后的《药品生产许可证》，11月03日股价上涨1.48%
每周股票复盘：天目药业（600671）股东户数降6.91%，前三季净利增484.48%
证券之星 · 2025-11-02
每周股票复盘：天目药业（600671）股东户数降6.91%，前三季净利增484.48%
天目药业(600671.SH)：前三季度净利润1420.88万元
中金财经 · 2025-10-28
天目药业(600671.SH)：前三季度净利润1420.88万元
股市必读：天目药业（600671）10月17日收盘跌5.3%，主力净流入1999.38万元
证券之星 · 2025-10-20
股市必读：天目药业（600671）10月17日收盘跌5.3%，主力净流入1999.38万元
天目药业（600671）披露上半年业绩扭亏为盈，9月29日股价下跌0.27%
证券之星 · 2025-09-29
天目药业（600671）披露上半年业绩扭亏为盈，9月29日股价下跌0.27%
每周股票复盘：天目药业（600671）上半年净利1024.78万元扭亏为盈
证券之星 · 2025-09-28
每周股票复盘：天目药业（600671）上半年净利1024.78万元扭亏为盈
天目药业(600671)9月19日股东户数1.04万户，较上期增加3.21%
证券之星 · 2025-09-24
天目药业(600671)9月19日股东户数1.04万户，较上期增加3.21%
天目药业(600671.SH)子公司收到药品再注册批准通知书
智通财经 · 2025-09-22
天目药业(600671.SH)子公司收到药品再注册批准通知书
每周股票复盘：天目药业（600671）取消监事会获股东高票通过
证券之星 · 2025-09-14
每周股票复盘：天目药业（600671）取消监事会获股东高票通过
每周股票复盘：天目药业（600671）股东户数增20.37%，净利增155.39%
证券之星 · 2025-08-31
每周股票复盘：天目药业（600671）股东户数增20.37%，净利增155.39%
天目药业（600671）2025年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 2025-08-29
天目药业（600671）2025年中报简析：营收净利润同比双双增长，应收账款上升
天目药业股价震荡下行 上半年净利润1024万元扭亏为盈
金融界 · 2025-08-27
天目药业股价震荡下行 上半年净利润1024万元扭亏为盈
图解天目药业中报：第二季度单季净利润同比增长158.71%
证券之星 · 2025-08-27
图解天目药业中报：第二季度单季净利润同比增长158.71%
加载更多
公司概况
公司名称：
杭州天目山药业股份有限公司
所属行业：
医药制造业
上市日期：
1993-08-23
主营业务：
杭州天目山药业股份有限公司的主营业务是医药研发、药品流通、医技培训服务、器械销售及大健康板块的生产及销售。公司的主要产品是医药制造、药品流通、医疗培训和大健康等。
发行价格：
1.00
{"stockData":{"symbol":"600671","market":"SH","secType":"STK","nameCN":"天目药业","latestPrice":17.31,"timestamp":1767164401000,"preClose":17.42,"halted":0,"volume":2700300,"delay":0,"changeRate":-0.0063,"floatShares":122000000,"shares":122000000,"eps":0.2723,"marketStatus":"已收盘","change":-0.11,"latestTime":"12-31 15:00:00","open":17.32,"high":17.85,"low":17.22,"amount":47075800,"amplitude":0.0362,"askPrice":17.31,"askSize":93,"bidPrice":17.3,"bidSize":12,"shortable":0,"etf":0,"ttmEps":0.2723,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":17.42,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":19.16,"lowLimit":15.68,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":121778885,"isCdr":false,"pbRate":31.66,"roa":"--","peRate":63.569592,"roe":"23.89%","epsLYR":0.1252,"committee":-0.816688,"marketValue":2108000000,"turnoverRate":0.0222,"status":1,"floatMarketCap":2107000000},"requestUrl":"/m/hq/s/600671","defaultTab":"news","newsList":[{"id":"2594242995","title":"每周股票复盘：天目药业（600671）股东会通过续聘会计师事务所议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2594242995","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594242995?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:59","pubTimestamp":1766865547,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，天目药业报收于17.08元，较上周的17.51元下跌2.46%。本周关注点公司公告汇总：股东会审议通过《关于续聘会计师事务所的议案》，同意股份数占出席会议股东所持有效表决权的98.9395%。上海泽昌律师事务所对本次会议进行见证，认为会议召集、召开程序及表决结果合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0239","600671","BK0086"],"gpt_icon":0},{"id":"2592902219","title":"天目药业（600671）披露全资子公司收到药品再注册批准通知书，12月18日股价上涨3.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902219","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592902219?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:39","pubTimestamp":1766068757,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，天目药业报收于17.65元，较前一交易日上涨3.16%，最新总市值为21.49亿元。公司近日发布公告称，其全资子公司黄山市天目药业有限公司收到安徽省药品监督管理局核准签发的《药品再注册批准通知书》，涉及知柏地黄丸、舒筋活血片、桂附地黄丸、归脾丸、安神补心丸、杜仲颗粒、黄连上清片等7个药品，药品批准文号有效期均延长至2030年11月。上述药品恢复生产前需经现场检查并抽验合格后方可上市销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800039216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0174","BK0239","600671"],"gpt_icon":0},{"id":"2591642100","title":"天目药业（600671）披露拟续聘2025年度审计机构，12月15日股价上涨1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642100?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:30","pubTimestamp":1765809030,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，天目药业报收于16.92元，较前一交易日上涨1.68%，最新总市值为20.6亿元。该股当日开盘16.62元，最高17.05元，最低16.47元，成交额达3123.7万元，换手率为1.52%。公司近日发布公告称，拟续聘尤尼泰振青会计师事务所为公司2025年度财务报告和内部控制审计机构，聘期一年。该事项已经公司第十二届董事会第十七次会议审议通过，2025年度预计审计费用不超过83万元，其中财务报告审计费用48万元，内部控制审计费用35万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500036062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0239","600671","BK0086"],"gpt_icon":0},{"id":"2589312813","title":"天目药业（600671）披露召开2025年第四次临时股东会通知，12月05日股价上涨1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589312813","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589312813?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:24","pubTimestamp":1764944673,"startTime":"0","endTime":"0","summary":"截至2025年12月5日收盘，天目药业报收于17.23元，较前一交易日上涨1.89%，最新总市值为20.98亿元。该股当日开盘16.78元，最高17.38元，最低16.78元，成交额达3395.56万元，换手率为1.63%。公司近日发布公告称，杭州天目山药业股份有限公司将于2025年12月22日召开2025年第四次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。股权登记日为2025年12月16日，A股股东可参与投票。股东可于12月19日前通过电子邮件完成登记。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500040632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0239","600671","BK0174"],"gpt_icon":0},{"id":"2583517186","title":"每周股票复盘：天目药业（600671）公司及子公担保余额达17,525.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583517186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583517186?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:02","pubTimestamp":1763236938,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，天目药业报收于18.95元，较上周的18.81元上涨0.74%。本周，天目药业11月11日盘中最高价报19.4元。天目药业当前最新总市值23.08亿元，在中药板块市值排名66/67，在两市A股市值排名5021/5165。本次担保在2025年度预计担保额度内，无需另行履行审议程序。截至公告日，公司及子公司实际对外担保余额为17,525.04万元，占最近一期经审计净资产的334.55%，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","600671","BK0174","BK0239"],"gpt_icon":0},{"id":"2582360326","title":"天目药业（600671）披露为子公司提供担保及子公司为公司提供担保的进展公告，11月11日股价上涨0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582360326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582360326?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:51","pubTimestamp":1762872682,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，天目药业报收于18.98元，较前一交易日上涨0.96%，最新总市值为23.11亿元。近日，杭州天目山药业股份有限公司发布关于为子公司提供担保及子公司为公司提供担保的进展公告。本次担保在2025年度预计担保额度内，无需另行履行审议程序。截至公告日，公司及子公司实际对外担保余额为17,525.04万元，占最近一期经审计净资产的334.55%，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0174","600671","BK0086"],"gpt_icon":0},{"id":"2581877643","title":"天目药业（600671）披露子公司取得换发后的《药品生产许可证》，11月05日股价下跌1.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581877643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581877643?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:36","pubTimestamp":1762353384,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，天目药业报收于18.7元，较前一交易日下跌1.84%，最新总市值为22.77亿元。该股当日开盘18.86元，最高19.05元，最低18.58元，成交额达4428.61万元，换手率为1.94%。公司近日发布公告称，其子公司黄山天目薄荷药业有限公司收到安徽省药品监督管理局换发的《药品生产许可证》。本次换证系原证即将到期，新证取得保障了子公司正常生产经营，不会对公司经营业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500040870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0239","BK0174","600671"],"gpt_icon":0},{"id":"2580214730","title":"天目药业（600671）披露子公司取得换发后的《药品生产许可证》，11月03日股价上涨1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580214730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580214730?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:50","pubTimestamp":1762181432,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘，天目药业报收于19.15元，较前一交易日上涨1.48%，最新总市值为23.32亿元。该股当日开盘19.05元，最高19.18元，最低18.88元，成交额达4084.7万元，换手率为1.76%。公司近日发布公告称，其全资子公司黄山市天目药业有限公司收到安徽省药品监督管理局换发的《药品生产许可证》，有效期至2030年12月31日。本次换发系原证到期换发，确保黄山天目正常生产经营，不会对公司经营业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300036413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","600671","BK0174","BK0239"],"gpt_icon":0},{"id":"2580093405","title":"每周股票复盘：天目药业（600671）股东户数降6.91%，前三季净利增484.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580093405","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580093405?lang=zh_cn&edition=full","pubTime":"2025-11-02 10:49","pubTimestamp":1762051746,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，天目药业报收于18.87元，较上周的19.28元下跌2.13%。业绩披露要点财务报告天目药业2025年三季报显示，公司主营收入1.59亿元，同比上升27.48%；归母净利润1420.88万元，同比上升484.48%；扣非净利润1088.3万元，同比上升238.38%。公司公告汇总杭州天目山药业股份有限公司2025年第三季度报告营业收入：本报告期55,343,038.75元，同比减少15.03%；年初至报告期末158,940,412.66元，同比增加27.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600671","BK0174","BK0239","BK0086"],"gpt_icon":0},{"id":"2578495485","title":"天目药业(600671.SH)：前三季度净利润1420.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578495485","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578495485?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:27","pubTimestamp":1761654424,"startTime":"0","endTime":"0","summary":"格隆汇10月28日丨天目药业(600671.SH)发布三季报，2025年前三季度实现营业总收入1.59亿元，同比增长27.48%；归属母公司股东净利润1420.88万元，上年同期亏损369.55万元；基本每股收益为0.1167元。\r\n\r\n \r\n\r\n 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251028/31745061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600671"],"gpt_icon":0},{"id":"2576070904","title":"股市必读：天目药业（600671）10月17日收盘跌5.3%，主力净流入1999.38万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576070904","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576070904?lang=zh_cn&edition=full","pubTime":"2025-10-20 02:06","pubTimestamp":1760897173,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，天目药业报收于18.4元，下跌5.3%，换手率9.87%，成交量12.01万手，成交额2.2亿元。交易信息汇总股价提醒10月17日天目药业收盘报18.4元，跌5.3%，当日成交1200.92万元。该股已连续2日下跌，近5个交易日中有2日跌幅超5%。前10个交易日主力资金累计净流出669.7万元，期间股价累计下跌0.55%。资金流向10月17日主力资金净流入1999.38万元，占总成交额9.1%；游资资金净流出409.33万元，占总成交额1.86%；散户资金净流出1590.05万元，占总成交额7.24%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000000802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0174","600671","BK0239"],"gpt_icon":0},{"id":"2571389877","title":"天目药业（600671）披露上半年业绩扭亏为盈，9月29日股价下跌0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571389877","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571389877?lang=zh_cn&edition=full","pubTime":"2025-09-29 17:42","pubTimestamp":1759138955,"startTime":"0","endTime":"0","summary":"截至2025年9月29日收盘，天目药业报收于18.26元，较前一交易日下跌0.27%，最新总市值为22.24亿元。截至2025年6月末，应收账款余额为1.29亿元，计提减值准备1,525.65万元，其中本期计提约202.48万元。前五大应收账款客户中部分为关联方，回款情况正常。公司表示，应收账款增长系业务扩张所致，相关风险可控。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900024489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0239","600671","BK0086"],"gpt_icon":0},{"id":"2570820891","title":"每周股票复盘：天目药业（600671）上半年净利1024.78万元扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2570820891","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570820891?lang=zh_cn&edition=full","pubTime":"2025-09-28 02:44","pubTimestamp":1758998653,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，天目药业报收于18.31元，较上周的17.9元上涨2.29%。本周，天目药业9月25日盘中最高价报18.87元。公司公告汇总杭州天目山药业股份有限公司关于对上海证券交易所信息披露监管工作函的回复公告公司披露2025年上半年营业收入1.04亿元，同比增长73.97%，净利润1024.78万元，扣非净利润590.33万元，均实现扭亏为盈。截至2025年6月末，应收账款余额1.29亿元，计提减值准备1,525.65万元，本期计提约202.48万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800000648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600671","BK0086","BK0239","BK0174"],"gpt_icon":0},{"id":"2569477449","title":"天目药业(600671)9月19日股东户数1.04万户，较上期增加3.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569477449","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569477449?lang=zh_cn&edition=full","pubTime":"2025-09-24 17:18","pubTimestamp":1758705533,"startTime":"0","endTime":"0","summary":"证券之星消息，近日天目药业披露，截至2025年9月19日公司股东户数为1.04万户，较7月31日增加324.0户，增幅为3.21%。在中药行业个股中，天目药业股东户数低于行业平均水平，截至9月19日，中药行业平均股东户数为5.29万户。从股价来看，2025年7月31日至2025年9月19日，天目药业区间涨幅为28.22%，在此期间股东户数增加324.0户，增幅为3.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092400029915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600671","BK0086","BK0239","BK0174"],"gpt_icon":0},{"id":"2569200332","title":"天目药业(600671.SH)子公司收到药品再注册批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2569200332","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569200332?lang=zh_cn&edition=full","pubTime":"2025-09-22 17:05","pubTimestamp":1758531942,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天目药业(600671.SH)发布公告，公司下属全资子公司黄山市天目药业有限公司(简称“黄山天目”)于近日收到安徽省药品监督管理局核准签发的六味地黄丸等多款《药品再注册批准通知书》。上述药品《再注册批准通知书》的取得，保障了公司药品生产、销售资质的稳定和延续，对公司后续的生产、销售、推广等具有积极的意义。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600671","BK0174","BK0086"],"gpt_icon":0},{"id":"2567139328","title":"每周股票复盘：天目药业（600671）取消监事会获股东高票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2567139328","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567139328?lang=zh_cn&edition=full","pubTime":"2025-09-14 05:45","pubTimestamp":1757799917,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，天目药业报收于18.58元，较上周的18.61元下跌0.16%。本周，天目药业9月12日盘中最高价报19.13元。天目药业当前最新总市值22.78亿元，在中药板块市值排名66/67，在两市A股市值排名4955/5153。本周关注点公司公告汇总：天目药业股东大会高票通过取消监事会及修订公司章程等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400001451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600671","BK0174","BK0086","BK0239"],"gpt_icon":0},{"id":"2563838837","title":"每周股票复盘：天目药业（600671）股东户数增20.37%，净利增155.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563838837","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563838837?lang=zh_cn&edition=full","pubTime":"2025-08-31 06:32","pubTimestamp":1756593148,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，天目药业报收于19.81元，较上周的18.0元上涨10.06%。本周，天目药业8月27日盘中最高价报21.01元，股价触及近一年最高点。业绩披露要点：2025年中报归母净利润1024.78万元，同比上升155.39%。股本股东变化截至2025年7月31日，公司股东户数为1.01万户，较6月30日增加1707.0户，增幅20.37%。2025年第二季度单季度主营收入5130.39万元，同比上升61.27%；单季度归母净利润515.35万元，同比上升158.71%；单季度扣非净利润224.58万元，同比上升119.87%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100002203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0086","BK0174","600671"],"gpt_icon":0},{"id":"2563062398","title":"天目药业（600671）2025年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2563062398","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563062398?lang=zh_cn&edition=full","pubTime":"2025-08-29 06:06","pubTimestamp":1756418807,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期天目药业发布2025年中报。截至本报告期末，公司营业总收入1.04亿元，同比上升73.97%，归母净利润1024.78万元，同比上升155.39%。按单季度数据看，第二季度营业总收入5130.39万元，同比上升61.27%，第二季度归母净利润515.35万元，同比上升158.71%。本报告期天目药业应收账款上升，应收账款同比增幅达260.4%。本次财报公布的各项数据指标表现尚佳。去年的净利率为10.06%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900005148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600671"],"gpt_icon":0},{"id":"2562316723","title":"天目药业股价震荡下行 上半年净利润1024万元扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2562316723","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562316723?lang=zh_cn&edition=full","pubTime":"2025-08-27 23:16","pubTimestamp":1756307794,"startTime":"0","endTime":"0","summary":"截至2025年8月27日15时，天目药业股价报19.36元，较前一交易日下跌3.87%。当日成交量为140593手，成交金额达2.81亿元，振幅为9.14%。天目药业主要从事中成药、西药、原料药及大健康领域的业务。公司实施\"精品中药\"战略，拥有25个品种的再注册批准文号。2025年半年报显示，公司实现营业收入1.04亿元，同比增长73.97%；归属于上市公司股东的净利润1024.78万元，实现扭亏为盈。其中第二季度营业收入5130万元，归母净利润515万元。公司净资产较年初增长19.56%至6263.17万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/27231652757820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600671"],"gpt_icon":0},{"id":"2562178997","title":"图解天目药业中报：第二季度单季净利润同比增长158.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562178997","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562178997?lang=zh_cn&edition=full","pubTime":"2025-08-27 18:25","pubTimestamp":1756290349,"startTime":"0","endTime":"0","summary":"证券之星消息，天目药业2025年中报显示，公司主营收入1.04亿元，同比上升73.97%；归母净利润1024.78万元，同比上升155.39%；扣非净利润590.33万元，同比上升126.76%；其中2025年第二季度，公司单季度主营收入5130.39万元，同比上升61.27%；单季度归母净利润515.35万元，同比上升158.71%；单季度扣非净利润224.58万元，同比上升119.87%；负债率76.97%，投资收益0.4万元，财务费用321.41万元，毛利率42.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700039363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600671"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767367333373,"stockEarnings":[{"period":"1week","weight":0.0082},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.052},{"period":"6month","weight":0.2803},{"period":"1year","weight":0.9715},{"period":"ytd","weight":0.9715}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州天目山药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9693人(较上一季度减少6.91%)","perCapita":"12557股","listingDate":"1993-08-23","address":"浙江省杭州市临安区锦南街道上杨路18号","registeredCapital":"12177万元","survey":" 杭州天目山药业股份有限公司的主营业务是医药研发、药品流通、医技培训服务、器械销售及大健康板块的生产及销售。公司的主要产品是医药制造、药品流通、医疗培训和大健康等。","listedPrice":1},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天目药业(600671)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天目药业(600671)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天目药业,600671,天目药业股票,天目药业股票老虎,天目药业股票老虎国际,天目药业行情,天目药业股票行情,天目药业股价,天目药业股市,天目药业股票价格,天目药业股票交易,天目药业股票购买,天目药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天目药业(600671)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天目药业(600671)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}